Kidney Disease

49-64 of 148

New opportunities to tackle the global burden of CKD – the role of SGLT2i
New opportunities to tackle the global burden of CKD – the role of SGLT2i
Sharing international experience in CKD & SGLT2i: How to identify the right patient at the right moment?
New opportunities to tackle the global burden of CKD – the role of SGLT2i
Adeera Levin, MD
- Adeera Levin, MD
Primary care role in CKD
Primary care role in CKD
4 things to know about CKD and SGLT2i
Primary care role in CKD
Prof. Richard Hobbs, MD
- Prof. Richard Hobbs, MD
A call to action: optimizing treatment in CKD
A call to action: optimizing treatment in CKD
4 things to know about CKD and SGLT2i
A call to action: optimizing treatment in CKD
Prof. Meg Jardine, MD, PhD
- Prof. Meg Jardine, MD, PhD
When and how to initiate SGLT2i in CKD
When and how to initiate SGLT2i in CKD
4 things to know about CKD and SGLT2i
When and how to initiate SGLT2i in CKD
Prof. David Wheeler, MD
- Prof. David Wheeler, MD
What is the evidence of SGLT2i in CKD?
What is the evidence of SGLT2i in CKD?
4 things to know about CKD and SGLT2i
What is the evidence of SGLT2i in CKD?
Prof. Hiddo L. Heerspink, PhD
- Prof. Hiddo L. Heerspink, PhD
Inflammation as a new target in CV risk reduction
Inflammation as a new target in CV risk reduction
Inflammation
Inflammation as a new target in CV risk reduction
Paul Ridker, MD
- Paul Ridker, MD
Optimizing GDMT in HFrEF and management of hyperkalemia
Optimizing GDMT in HFrEF and management of hyperkalemia
Kidney Disease
Optimizing GDMT in HFrEF and management of hyperkalemia
Prof. Mikhail Kosiborod
- Prof. Mikhail Kosiborod
New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle
New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle
Kidney Disease
New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle
Prof. Mikhail Kosiborod; Prof. Austin G. Stack, MD
- Prof. Mikhail Kosiborod
- Prof. Austin G. Stack, MD
A new option for cardiorenal protection for patients with CKD and T2DM
A new option for cardiorenal protection for patients with CKD and T2DM
Kidney Disease
A new option for cardiorenal protection for patients with CKD and T2DM
Prof. Gerasimos S. Filippatos, MD; Javier Morales, MD
- Prof. Gerasimos S. Filippatos, MD
- Javier Morales, MD
- Angela Yee-Moon Wang, MD, PhD
Reducing morbidity and mortality in patients with CKD and T2DM
Reducing morbidity and mortality in patients with CKD and T2DM
Kidney Disease
Reducing morbidity and mortality in patients with CKD and T2DM
Pam R. Taub, MD, FACC, FASPC; Prof. George Bakris, MD
- Pam R. Taub, MD, FACC, FASPC
- Prof. George Bakris, MD
- Prof. Gerasimos Filippatos, MD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
AHA 2022
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
David Preiss, PhD
- David Preiss, PhD
SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia
SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia
Is HFpEF hiding in your practice? An expert debate on the emerging role of diabetologists
SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia
Prof. Silvio Inzucchi
- Prof. Silvio Inzucchi
The spectrum of therapeutic options: which therapies to consider?
The spectrum of therapeutic options: which therapies to consider?
The challenge of choosing in cardiovascular risk management
The spectrum of therapeutic options: which therapies to consider?
Prof. Ulf Landmesser
- Prof. Ulf Landmesser
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
EASD 2022
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
Pardeep Jhund, MD, PhD
- Pardeep Jhund, MD, PhD
SGLT2i improves outcomes in HFpEF and HFmrEF
SGLT2i improves outcomes in HFpEF and HFmrEF
ESC 2022
SGLT2i improves outcomes in HFpEF and HFmrEF
Scott Solomon, MD
- Scott Solomon, MD
Totality of evidence of SGLT2 inhibition in HF
Totality of evidence of SGLT2 inhibition in HF
ESC 2022
Totality of evidence of SGLT2 inhibition in HF
Muthiah Vaduganathan, MD
- Muthiah Vaduganathan, MD

4/9